Languages  By theme  By sector  By country
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
SANOFI-AVENTIS [FR0000120578/SAN]   
[12/09/2013]

SANOFI-AVENTIS : Sanofi Provides Update on Lixisenatide New Drug Application in U.S.

PRESS RELEASE Sanofi Provides Update on Lixisenatide New Drug Application in U.S. Paris, France - September 12, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today its decision to withdraw the lixisenatide New Drug Application (NDA) in the U.S., which included early interim results from the ongoing ELIXA cardiovascular (CV) outcomes study. The company plans to resubmit... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[03/09/2013]

SANOFI-AVENTIS : Menomune® Is the First Quadrivalent Meningococcal Vaccine Prequalified by the WHO

PRESS RELEASE Menomune(r) Is the First Quadrivalent Meningococcal Vaccine Prequalified by the WHO - Prequalification Makes the Vaccine Eligible for Purchase by United Nations Agencies - Lyon, France - September 3, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY),... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[30/08/2013]

SANOFI-AVENTIS : European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)

PRESS RELEASE European Commission Approves Genzyme's Once-Daily, Oral Multiple Sclerosis Treatment Aubagio(r) (teriflunomide) Paris, France - August XX, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Commission has granted marketing authorization for Aubagio(r) (teriflunomide) 14 mg, a once-daily, oral... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[30/08/2013]

SANOFI-AVENTIS : Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Reg

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French société... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[29/08/2013]

SANOFI-AVENTIS : Sanofi successfully prices EUR 1 billion bond issue

PRESS RELEASE Sanofi successfully prices EUR 1 billion bond issue Paris, France - August 29, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of EUR 1 billion of notes, due 2020, bearing interest at an annual rate of 1.875%. The issue is drawn under the Company's Euro Medium Term Note Programme. Sanofi intends to... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[26/08/2013]

SANOFI-AVENTIS : Sanofi Pasteur’s Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older

PRESS RELEASE Sanofi Pasteur's Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older - Efficacy trial in more than 30,000 older adults meets primary endpoint for superior efficacy - Lyon, France - August 26, 2013 -... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[05/08/2013]

SANOFI-AVENTIS : Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium Difficile Vaccine

PRESS RELEASE Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium Difficile Vaccine - Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide - Lyon, France - August 5, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and... See more
 
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
Videos
Gestionnaires,
Emetteurs,
My favourite companies
Most read news of SANOFI-AVENTIS
Dissemination technology Webdisclosure.com - copyright 2020 SYMEX ECONOMICS all rights reserved